CON vs ASTH

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

CON

34.9
AI Score
VS
ASTH Wins

ASTH

49.7
AI Score

Investment Advisor Scores

CON

35score
Recommendation
SELL

ASTH

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CON ASTH Winner
Revenue 1.18B 1.94B ASTH
Net Income 115.79M 34.17M CON
Net Margin 9.8% 1.8% CON
Operating Income 210.68M 62.85M CON
ROE 24.3% 4.1% CON
ROA 3.8% 1.5% CON
Total Assets 3.01B 2.28B CON
Cash 158.04M 400.79M ASTH
Current Ratio 1.38 1.23 CON
Free Cash Flow 129.48M 92.93M CON

Relative Price Performance (Last 90 Days)

CON 1M: +12.1% · 3M: +24.0% ASTH 1M: +6.4% · 3M: -8.9%

Current Technical Phase

CON

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 71

RSI (14): 70.9 · Price: $39.09

ASTH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.7 · Price: $37.35

Fundamentals Snapshot

Metric CON ASTH
Market Cap — —
Forward P/E 21.2 10.3
Trailing P/E 25.0 46.5
Revenue (TTM) — —
Revenue Growth 0.1% 0.5%
Gross Margin 0.3% 0.1%
Operating Margin 0.2% 0.0%
EPS 1.55 0.83
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, ASTH is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.